GlaxoSmithKline Announces Approval and Availability of Avandaryl


By: Daniel Trecroci

GlaxoSmithKline announced the availability of Avandaryl (rosiglitazone maleate and glimepiride), a new fixed-dose combination product for type 2 diabetes.

“Recently approved by the U.S. Food and Drug Administration, Avandaryl is the first and only tablet to combine a thiazolidinedione [Avandia], with a sulfonylurea [Amaryl], to help improve blood sugar control,” says GlaxoSmithKline. “As an adjunct to diet and exercise, Avandaryl is indicated to improve blood sugar control in patients with type 2 diabetes who are already treated with a combination of [Avandia] and sulfonylurea, or who are not adequately controlled on a sulfonylurea alone, or for those patients who have initially responded to [Avandia] alone and require additional blood sugar control.”

Avandaryl is available in three tablet strengths: 4 mg/1 mg, 4 mg/2 mg and 4 mg/4 mg.

For more information about Avandaryl, log on to or call (888) 825-5249.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.